SBIR Phase I: Bioactive, High-Strength Contrast Agents for Orthopedic and Bone Applications

这个小型企业创新研究(SBIR)第一阶段项目旨在开发用于整形外科和骨植入应用的生物活性、高强度造影剂。临床上显然需要改进的造影剂，以增加骨-空洞填充物的强度、韧性和磨损，改善其生物相容性，并促进骨/填充物界面上健康骨的生长。这项创新解决了目前的缺点，旨在生产能够改善机械性能、疲劳寿命、磨损和与活骨的生物相容性的造影剂。该项目的更广泛的影响/商业潜力是提高全关节置换手术的成功率，延长植入物的寿命，并降低翻修手术的比率。涉及髋关节和膝关节置换的手术(以及其他使用骨空洞填充物的手术)在全球范围内迅速增加，而在更年轻的患者群体中进行这些手术的趋势预示着未来几十年它们的发病率将大幅增加。

This Small Business Innovation Research (SBIR) Phase I project seeks to develop bioactive, high-strength contrast agents for use in orthopedic and bone implant applications. There is a clear clinical need for improved contrast agents that increase the strength, toughness and abrasion wear of bone-void fillers, improve its biocompatibility and ability to promote the growth of healthy bone at the bone/filler interface. The innovation addresses the current shortcomings and aims to produce contrast agents that improve the mechanical properties, fatigue life, wear abrasion, and bio-compatibility with living bone. The broader impact/commercial potential of this project is to increase the success rate of total joint replacement surgeries, increase the implant lifetime and reduce the rates of revision surgeries. Surgeries involving hip and knee replacements (and other surgeries utilizing bone-void fillers) are rapidly increasing world-wide, and the trend toward performing these surgeries on a younger patient population, who will more likely require replacement surgeries, portends a massive increase in their incidence in the coming decades.